Parcourir médecine/sciences 2015 vol.31 par auteur "Jordan, Bertrand"

Voici les éléments 1-12 de 12

    • Les années 2000 

      Peschanski, Marc; Bergeron, Michel; Boué, André; Coppens, Yves; Changeux, Jean-Pierre; Corvol, Pierre; Lazar, Philippe; Kahn, Axel; Bichet, Daniel G.; Friedlander, Gérard; Epelbaum, Jacques; Kroemer, Guido; Chneiweiss, Hervé; Munnich, Arnold; Bouvier, Michel; Jordan, Bertrand; Frydman, René; Morange, Michel; Fougereau, Michel (Éditions EDK, Groupe EDP Sciences, 2015)

    • Les années 2010 

      Bouvier, Michel; Chneiweiss, Hervé; Jordan, Bertrand; Lagrue, Gilbert; Ménard, Joël; Teillaud, Jean-Luc; Kroemer, Guido; Moulin, Anne-Marie; Flahault, Antoine; Lafanechère, Laurence; Maréchal, Éric; Guillemot, Jean-Claude; Gaille, Marie (Éditions EDK, Groupe EDP Sciences, 2015)

    • Chroniques génomiques - 23andMe ou comment (très bien) valoriser ses clients 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      The announcement of several deals between the DTC genetics firm 23andMe and Genentech, Pfizer and other corporations reveals the real business model of the company: selling access to sets of characterized patients for ...

    • Chroniques génomiques - Biopsies liquides, une révolution en cancérologie ? 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      The detection and analysis of circulating tumour DNA and/or circulating tumour cells in the blood of cancer patients open new possibilities for cancer characterisation and management. The approach has generated much ...

    • Chroniques génomiques - CRISPR-Cas9, une nouvelle donne pour la thérapie génique 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      Targeted modification of genes (“gene editing”) is made much easier by the recently developed CRISPR-Cas9 system. This has raised alarm about possible uses of this technology for germline modification of the human genome; ...

    • Chroniques génomiques - Des résultats tout à fait inattendus 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      There are now a number of cases in which non-invasive prenatal testing (NIPT) has detected signs of cancer in pregnant women. These unexpected findings raise a number of difficult questions regarding their communication ...

    • Chroniques génomiques - Dépistage du cancer : les promesses illusoires de Pathway Genomics 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      The “liquid biopsy” approach shows promise for characterization and monitoring of cancer during treatment; however a blood-based detection test for “high-risk” but asymptomatic individuals, recently introduced by Pathway ...

    • Chroniques génomiques - Du bon usage d’un test non invasif 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)

    • Chroniques génomiques - Encore le « gène du crime » ? 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      A new genetic study focussing on the degree of violence in criminals and using both candidate gene and GWAS approaches finds statistically significant associations of extreme violent behaviour with low activity alleles of ...

    • Chroniques génomiques - Séquencer les bébés ? 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      An extension of newborn screening to genome sequencing is now feasible but raises a number of scientific, organisational and ethical issues. This is being explored in discussions and in several funded trials, in order to ...

    • Chroniques génomiques - Thérapie génique germinale, le retour ? 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      The recent development of a powerful and flexible genome editing technique (the CRISP-cas9 method) accelerates tremendously the production of animal models and will significantly enhance the perspectives of (somatic) gene ...

    • Recherche cibles, désespérément : Chroniques génomiques 

      Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)
      In clinical oncology, obtaining sequence data from tumour samples has become practical in terms of logistics, turnover time and costs. The major issue now is the interpretation of this sequence to define actionable targets, ...